0001104659-19-023738.txt : 20190425 0001104659-19-023738.hdr.sgml : 20190425 20190425170926 ACCESSION NUMBER: 0001104659-19-023738 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190424 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20190425 DATE AS OF CHANGE: 20190425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Innoviva, Inc. CENTRAL INDEX KEY: 0001080014 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943265960 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30319 FILM NUMBER: 19768333 BUSINESS ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 500 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 6502389600 MAIL ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY STREET 2: SUITE 500 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: THERAVANCE INC DATE OF NAME CHANGE: 20020207 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MEDICINE INC DATE OF NAME CHANGE: 20000302 8-K 1 a19-8872_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934

 

Date of Report (Date of earliest event reported): April 24, 2019

 

 

INNOVIVA, INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

 

000-30319

 

94-3265960

(State or Other Jurisdiction of Incorporation)

 

(Commission File Number)

 

(I.R.S. Employer Identification Number)

 

2000 Sierra Point Parkway
Suite 500

Brisbane, California 94005

(650) 238-9600

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

 

 

 

Item 5.07.     Submission of Matters to a Vote of Security Holders.

 

At the Annual Meeting of Stockholders held on April 24, 2019 (the “Meeting”), our stockholders elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2020, as follows:

 

Members

 

Number of
Shares Voted
For

 

Number of
Shares Voted
Against or
Abstained

 

Broker
Non-Votes

 

George W. Bickerstaff, III

 

54,197,851

 

1,521,496

 

8,146,532

 

Mark DiPaolo, Esq.

 

55,331,131

 

388,216

 

8,146,532

 

Jules Haimovitz

 

55,300,377

 

418,970

 

8,146,532

 

Odysseas D. Kostas, M.D.

 

55,209,263

 

510,084

 

8,146,532

 

Sarah Schlesinger, M.D.

 

55,174,609

 

544,738

 

8,146,532

 

 

At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s 2018 executive compensation. The vote for such approval was 54,969,304 shares for, 601,715 shares against, 148,328 shares abstaining, and 8,146,532 shares of broker non-votes.

 

Also at the Meeting, our stockholders ratified the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019. The vote for such ratification was 63,005,811 shares for, 691,647 shares against, 168,421 shares abstaining and no broker non-votes.

 

2

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

INNOVIVA, INC.

Date: April 25, 2019

 

By:

/s/ Geoffrey Hulme

 

 

 

Geoffrey Hulme

 

 

 

Interim Principal Executive Officer

 

3